In-article:

PREDILIFE: 2021 ANNUAL RESULTS: ACCELERATION OF GROWTH DRIVEN BY COMPANY OFFERS – 04/25/2022 at 07:00


2021 ANNUAL RESULTS: ACCELERATION OF GROWTH DRIVEN BY CORPORATE OFFERS

Villejuif, France, April 25, 2022 at 7:00 a.m. CET – PREDILIFE

(Euronext Growth: ALPRE FR0010169920) (the “

Company

), a specialist in innovative pathology risk prediction solutions for personalized medicine, today announces its 2021 annual results, approved by the Board of Directors on April 22, 2022. Audit procedures for the parent company and consolidated financial statements were carried out by the auditors.

Stéphane Ragusa, Chairman and Chief Executive Officer of the Company declares:

“The launch in the fall of an offer of prevention assessments for companies has met with a promising welcome. Beneficiary employees were enthusiastic about an offer of health check-ups previously reserved for senior executives. We will continue to roll it out through direct and indirect marketing via brokers, mutuals and insurers. The market concerns all employees in France and beyond our borders. Our association with international players such as Eurofins Scientific, which carries out genetic tests, or Marsch-Mercer, the world’s leading broker, gives us the ability to deploy our predictive medicine offer internationally.”

Analysis of annual results

In K€

2021

2020

Turnover

142.1

51.6

Other exploitation products

53.8

230.6

Exploitation charges

(3,716.7)

(2,769.4)

Operating result

(3,520.8)

(2,487.2)

Net profit

(3,413.8)

(2,250.6)

Cash and cash equivalents at closing

2,821.9

3,149.5

During the 2021 financial year, the Group generated revenue of €142.1 thousand compared to revenue of €51.6 thousand in 2020, up thanks to the launch in the second half of 2021 of predictive balance sheets for companies.

During the year, PREDILIFE continued its investment efforts to launch its multi-pathology risk prediction report.

The operating loss amounted to €3,520.8 K in 2021 compared to an operating loss of €2,487.2 K for the previous financial year. The net loss for the 2021 financial year thus amounts to €3,413.8 thousand compared to a net loss of €2,250.6 thousand for the 2020 financial year.

As of December 31, 2021, the Group’s cash position amounted to €2,821.9 thousand compared to €3,149.5 thousand at the end of the previous financial year, benefiting in particular from the proceeds of the capital increase carried out at the end of of year.

In order to ensure the continuation of its development, Predilife carried out in April 2021, a public offering of bonds convertible or exchangeable into new or existing shares (“OCEANE”), which was subscribed for €2.5 million. then a capital increase by Public Offer, which raised funds of €1.1 million in December 2021.

Availability of the 2021 annual financial report

The annual financial report as of December 31, 2021, including the management report, the 2021 annual and consolidated financial statements as well as the reports of the statutory auditors on said financial statements, will be made available to the public no later than April 30, 2022. It will be available on the Predilife website, https://www.predilife.com, in the Investors/financial reports section.

contacts

Investor Relations

PREDILIFE

Stephane Ragusa

Chairman and CEO

Press relations

CAPVALUE

01 80 81 50 00

[email protected]

About PREDILIFE

PREDILIFE is a pioneering company in the design and development of predictive tests that can allow each person to define their risk profile for the occurrence of serious illnesses. It uses artificial intelligence methods applied to clinical medical data, genetics, imaging… PREDILIFE markets in Europe Mammorisk®, a breast cancer risk prediction test. The Company has also begun to extend this offer to other serious pathologies.

For more information: https://www.predilife.com

Warning

This release contains non-factual materials, including, but not limited to, certain statements regarding future results and other future events. These statements are based on the current view and assumptions of the Company’s management. They incorporate known and unknown risks and uncertainties that could cause actual results, profitability and expected events to differ materially. In addition, Predilife, its shareholders and its respective affiliates, directors, officers, councils and employees have not verified the accuracy of, and make no representations or warranties about, the statistical information or the forward-looking information contained in this press release. which are or are derived from third party sources or industry publications. These statistical data and forward-looking information are used in this press release for informational purposes only.


This post has the “🔒 Actusnews SECURITY MASTER” service.


– SECURITY MASTER Key:

mnBtYZlsaJiZx22eZppqm5OWb2xkm2XKmZPKk2NqlZeYbp+Vm2hhZsXLZnBllmVr

– To check this key:

https://www.security-master-key.com.



Regulated information:


Inside information:

– Press release on accounts, results


Full and original press release in PDF format:

https://www.actusnews.com/news/74105-v2_mr_ak-revu-capvalue_valide1-2-1.pdf

© Copyright Actusnews Wire

Receive the company’s next press releases free of charge by email by subscribing to www.actusnews.com



Source link -86